lipid-lowering drug

出典: meddic

antilipemic agentantilipemic drughypolipidemichypolipidemic agenthypolipidemic drughypolipidemicslipid-lowering agent

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • Secondary prevention in patients after hospitalization due to coronary artery disease - what has changed since 2006?
  • Jankowski P, Czarnecka D, Lysek R, Skrzek A, Smaś-Suska M, Mazurek A, Brzozowska-Kiszka M, Wolfshaut-Wolak R, Surowiec S, Bogacki P, Bryniarska-Mirek E, Bryniarski L, Grodecki J, Nessler J, Olszowska M, Podolec P, Kawecka-Jaszcz K, Pająk A.Author information I Department of Cardiology and Hypertension, Institute of Cardiology, Jagiellonian University Medical College, Krakow. piotrjankowski@interia.pl.AbstractBACKGROUND: The evidence concerning the quality of secondary prevention of coronary artery disease (CAD) in Poland in recent years is scarce.
  • Kardiologia polska.Kardiol Pol.2014 Jan 10. doi: 10.5603/KP.a2013.0350. [Epub ahead of print]
  • BACKGROUND: The evidence concerning the quality of secondary prevention of coronary artery disease (CAD) in Poland in recent years is scarce.AIM: to compare the implementation of secondary prevention guidelines into everyday clinical practice between 2006/2007 and 2011/2012 in patients after hospita
  • PMID 24408064
  • Development of optimized supersaturable self-nanoemulsifying systems of ezetimibe: effect of polymers and efflux transporters.
  • Bandyopadhyay S, Katare O, Singh B.Author information Global Institute of Pharmaceutical Education and Research, Division of Pharmaceutics and Biopharmaceutics, QbD Optimization Laboratory , Udham Singh Nagar, Uttarakhand 244713, Kashipur, 244713 , India.AbstractObjectives: To develop an optimized supersaturable self-nanoemulsifying drug delivery system (S-SNEDDS) in order to control drug precipitation along with surmounting poor aqueous solubility and P-glycoprotein (P-gp) and multidrug resistance protein 2 (MRP2) efflux activity. Methods: Long-term stability of a previously reported formulation (OPT-LCT) consisting of Maisine 35-1 and Labrasol indicated rapid precipitation of ezetimibe. In vitro supersaturation test was carried out for selection of apt polymeric precipitation inhibitor (PPI). Following incorporation of the selected PPI, the precipitates from various formulations were differentiated employing optical microscopy, differential scanning calorimetry (DSC) and X-ray diffraction techniques. The S-SNEDDS was evaluated for globule size distribution. Also, lipid-lowering activity of S-SNEDDS was compared in relation to marketed product and optimized-long chain triglyceride. Subsequently, in situ perfusion studies were carried out for calculating various permeability and absorptivity parameters with specific focus on P-gp and MRP2 inhibition. Results: Supersaturation test facilitated the selection of HPMC E5LV as the best PPI. The precipitates from the S-SNEDDS were identified as amorphous while crystalline ezetimibe precipitates were found when HPMC was absent in the formulation. Owing to heterogeneous distribution, globule size analysis was not practicable. Plasma lipid estimations showed that S-SNEDDS had considerable influence in increasing the high-density lipid levels. The single-pass intestinal perfusion parameters, namely fraction absorbed and effective permeability demonstrated significant improvement in rate and extent of absorption from S-SNEDDS. Co-administration of itraconazole and indomethacin as P-gp and MRP2 inhibitors, respectively revealed the potential of S-SNEDDS in reducing the efflux activities. Conclusions: The studies revealed that the systemic exposure of ezetimibe following oral administration can be substantially improved using S-SNEDDS.
  • Expert opinion on drug delivery.Expert Opin Drug Deliv.2014 Jan 6. [Epub ahead of print]
  • Objectives: To develop an optimized supersaturable self-nanoemulsifying drug delivery system (S-SNEDDS) in order to control drug precipitation along with surmounting poor aqueous solubility and P-glycoprotein (P-gp) and multidrug resistance protein 2 (MRP2) efflux activity. Methods: Long-term stabil
  • PMID 24386966
  • Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.
  • Fitzgerald K1, Frank-Kamenetsky M2, Shulga-Morskaya S2, Liebow A2, Bettencourt BR2, Sutherland JE2, Hutabarat RM2, Clausen VA2, Karsten V2, Cehelsky J2, Nochur SV2, Kotelianski V2, Horton J3, Mant T4, Chiesa J5, Ritter J4, Munisamy M5, Vaishnaw AK2, Gollob JA2, Simon A2.Author information 1Alnylam Pharmaceuticals, Cambridge, MA, USA. Electronic address: kfitzgerald@alnylam.com.2Alnylam Pharmaceuticals, Cambridge, MA, USA.3Internal Medicine and Molecular Genetics, University of Texas South Western, Dallas, TX, USA.4Quintiles Drug Research Unit at Guy's Hospital, London, UK.5Covance Clinical Research Unit, Leeds, UK.AbstractBACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors, leading to their degradation. Genetics studies have shown that loss-of-function mutations in PCSK9 result in reduced plasma LDL cholesterol and decreased risk of coronary heart disease. We aimed to investigate the safety and efficacy of ALN-PCS, a small interfering RNA that inhibits PCSK9 synthesis, in healthy volunteers with raised cholesterol who were not on lipid-lowering treatment.
  • Lancet.Lancet.2014 Jan 4;383(9911):60-8. doi: 10.1016/S0140-6736(13)61914-5. Epub 2013 Oct 3.
  • BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors, leading to their degradation. Genetics studies have shown that loss-of-function mutations in PCSK9 result in reduced plasma LDL cholesterol and decreased risk of coronary heart disease. We aimed to investigate
  • PMID 24094767

和文文献

  • In Vivo Evaluation of 1-Benzyl-4-aminoindole-Based Thyroid Hormone Receptor β Agonists : Importance of Liver Selectivity in Drug Discovery
  • Takahashi Naoki,Asano Yukiyasu,Maeda Koji [他]
  • Biological & pharmaceutical bulletin 37(7), 1103–1108, 2014-07
  • NAID 40020103453
  • Anti-atherogenic Effects of a New Thienylacylhydrazone Derivative, LASSBio-788, in Rats Fed a Hypercholesterolemic Diet
  • da Motta Nadia Alice Vieira,Kummerle Arthur Eugen,Marostica Elisabeth [他],Fernandes dos Santos Caroline,Manssour Fraga Carlos Alberto,Barreiro Eliezer Jesus,Palhares de Miranda Ana Luisa,de Brito Fernanda Carla Ferreira
  • Journal of Pharmacological Sciences, 47-57, 2013
  • … Our results suggest that the compound LASSBio-788 represents a new multi-targeted drug candidate for the treatment of atherosclerosis. …
  • NAID 130003362739
  • Design and Characterization of Nanocrystal Formulations Containing Ezetimibe
  • Gulsun Tugba,Gursoy Reyhan Neslihan,Oner Levent
  • Chemical and Pharmaceutical Bulletin 59(1), 41-45, 2011
  • … Ezetimibe is a lipid-lowering compound that selectively inhibits the absorption of cholesterol and related phytosterols from the intestine. … Thus, the objective of this study was to improve the solubility and dissolution rate of ezetimibe by preparing drug nanocrystals utilizing ball milling, high speed homogenization techniques. …
  • NAID 130000405486

関連リンク

One great leap for lipid lowering drugs.. Cardiovasc J S Afr. 2002 Sep-Oct; 13(5):265-6. [Cardiovasc J S Afr. 2002] Editorial: Lipid-lowering drugs after myocardial infarction.. Lancet. 1975 Mar 1; 1(7905):501-2. [Lancet. 1975] Is ...
They are often combined with other lipid-lowering drugs. One problem with the bile acid resins is that they can increase triglycerides. Also, due to potential drug interactions, bile acid resins must be taken two hours before or after most drugs, including ARVs. For these reasons, most experts don't ...

関連画像

List of cholesterol lowering drugsLipid Lowering Agents , treatment arm and lipid-lowering drugsAvailable Lipid-Lowering DrugsLipid regulating agents; Lipid Regulating Lipid lowering drugs prescription and the


★リンクテーブル★
リンク元高脂血症治療薬」「lipid-lowering agent」「hypolipidemic」「抗高脂血症剤」「antilipemic drug
関連記事lip」「lowering」「drug」「lipid

高脂血症治療薬」

  [★]

lipid-lowering drug, lipid-lowering agent
脂質異常症
  Cho TG LDL-C↓ HDL-C↑ TG↓ 副作用
HMG-CoA還元酵素阻害薬 Choの合成阻害
→LDL受容体増加
    発疹、胃不快感、肝障害、
筋肉痛、筋脱力、横紋筋融解症
フィブラート系薬物   VLDL産生抑制
→VLDL,IDL異化促進
単独で、横紋筋融解症
腹痛、下痢、嘔吐などの腹部症状、肝障害
ニコチン酸系薬 VLDL分泌抑制 皮膚、特に顔面および上半身の紅潮、掻痒感
肝障害、胃腸障害、耐糖能の悪化、尿酸値上昇
陰イオン交換樹脂系薬物 胆汁酸再吸収抑制       腹部膨満感、便秘、肝障害
ビフェニル化合物 Choの胆汁排泄促進       肝障害、胃腸障害、耐糖能の悪化、尿酸値上昇発疹
まれにQT延長にともなう不整脈
EPA製剤   VLDL産生抑制
→VLDL異化促進
    胃部不快感、腹痛、下痢などの腹部症状
肝障害、出血傾向

高脂血症治療薬一覧

lipid-lowering agent」

  [★]

antilipemic agentantilipemic drughypolipidemichypolipidemic agenthypolipidemic drughypolipidemicslipid-lowering drug

hypolipidemic」

  [★]

  • adj.
  • 脂質低下性の、脂質低下の
  • n.
antilipemic agentantilipemic drughypolipidemic agenthypolipidemic drughypolipidemicslipid-loweringlipid-lowering agentlipid-lowering drug


抗高脂血症剤」

  [★]

lipid-lowering druglipid-lowering agenthypolipidemic drug
抗高脂血症薬抗脂血剤抗脂血薬抗高脂血薬抗高脂血剤高脂血症薬高脂血症治療薬


antilipemic drug」

  [★]

antilipemic agenthypolipidemichypolipidemic agenthypolipidemic drughypolipidemicslipid-lowering agentlipid-lowering drug

lip」

  [★]

  • n.

WordNet   license wordnet

「(botany) either of the two parts of a bilabiate corolla or calyx」

WordNet   license wordnet

「either the outer margin or the inner margin of the aperture of a gastropod''s shell」

WordNet   license wordnet

「either of two fleshy folds of tissue that surround the mouth and play a role in speaking」

PrepTutorEJDIC   license prepejdic

「〈C〉『くちびる』,口もと / 《複数形で》(発音器官としての)くちびる,口 / 〈U〉《俗》生意気な言葉 / 〈C〉(容器などの)口,へり,縁;(峡谷・火山などの)口 / 〈C〉(植物の)唇弁(しんべん)」

lowering」

  [★]

  • n.
declinedecreasedepressiondropfalllowerreduction

WordNet   license wordnet

「the act of causing something to move to a lower level」
letting down

WordNet   license wordnet

「the act of causing to become less」

PrepTutorEJDIC   license prepejdic

「低くする,低下させる;堕落させる」

PrepTutorEJDIC   license prepejdic

「(空模様が)険悪な,荒れ模様の / しかめっつらの,(顔つきが)不機嫌な」

drug」

  [★]

drugs

WordNet   license wordnet

「use recreational drugs」
do drugs

WordNet   license wordnet

「administer a drug to; "They drugged the kidnapped tourist"」
dose

WordNet   license wordnet

「a substance that is used as a medicine or narcotic」

PrepTutorEJDIC   license prepejdic

「『薬』,薬品,薬剤 / 『麻薬』,麻酔剤 / 〈人〉‘に'薬(特に麻酔剤)を与える / 〈飲食物〉‘に'(麻酔薬・毒薬などの)薬を混ぜる」

lipid」

  [★] 脂質

WordNet   license wordnet

「an oily organic compound insoluble in water but soluble in organic solvents; essential structural component of living cells (along with proteins and carbohydrates)」
lipide, lipoid

PrepTutorEJDIC   license prepejdic

「脂質,あぶら」



★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡